Advertisement
Canada markets open in 6 hours 7 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7307
    +0.0010 (+0.13%)
     
  • CRUDE OIL

    83.02
    +0.21 (+0.25%)
     
  • Bitcoin CAD

    88,031.03
    -3,438.20 (-3.76%)
     
  • CMC Crypto 200

    1,389.94
    +7.36 (+0.53%)
     
  • GOLD FUTURES

    2,333.10
    -5.30 (-0.23%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,451.50
    -213.00 (-1.21%)
     
  • VOLATILITY

    15.97
    0.00 (0.00%)
     
  • FTSE

    8,091.78
    +51.40 (+0.64%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Have Gilead's Gains Evaporated in the Coronavirus Treatment Race?

Have Gilead's Gains Evaporated in the Coronavirus Treatment Race?

Gilead Sciences (NASDAQ: GILD) started the year strong. As a result, while the rest of the stock market slid, Gilead did just the opposite. To make matters worse, the World Health Organization (WHO) recently advised against using remdesivir as a treatment for COVID-19.